Nov 03, 2025 7:05am EST Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
Oct 30, 2025 7:05am EDT Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference
Oct 28, 2025 7:05am EDT Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
Aug 26, 2025 7:00am EDT Unicycive Therapeutics to Participate in Upcoming Investor Events in September
Aug 18, 2025 7:05am EDT Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease
Aug 14, 2025 7:00am EDT Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
Jul 24, 2025 8:00am EDT Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology
Jul 08, 2025 8:30am EDT Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Jul 07, 2025 7:00am EDT Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Jun 30, 2025 7:05am EDT Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
